INTRODUCTION
Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder associated with altered stool habits and chronic abdominal pain without evidence of specific structural or biochemical abnormalities. 1 The overall prevalence of IBS in North America is estimated at 10-24%, [2] [3] [4] and likewise in Europe at 4-28%. 5 Women represent up to two-thirds of the IBS patients. 6, 7 The disease has a considerable impact on patients' health and lifestyle as well as on the economy and health-care system, with IBS patients accounting for up to 12% of all visits to general practitioners and 20-50% of all referrals to gastroenterologists. [8] [9] [10] The exact etiology and pathophysiological mechanisms associated with the clinical symptoms of chronic functional bowel disorders remain incompletely understood. 11 Various pathophysiological mechanisms 12 have been postulated, including visceral afferent hypersensitivity, [13] [14] [15] [16] [17] microscopic inflammation, 18, 19 post-infectious IBS, 20 alteration in fecal microflora, 21, 22 psychosocial dysfunction 23 and alteration in gastrointestinal motility. 24, 25 Women suffer more frequently from symptoms of IBS. In a review by Chang and Heitkemper, the sex ratio of patients who seek health care for IBS and other functional bowel disorders is calculated as 2-2.5:1 of women to men, or even 3-4:1. 26 Wilson et al. counted a prevalence of 6.6% of men and 14% of women in Birmingham with these disorders. 6 Interestingly, symptom intensity is also increased in women. 27 The reasons for these sex differences are still hypothetical, involving differences in stress reactivity, inflammatory responses and response to pain and sexual hormones. 11, 28, 29 Heitkemper and Chang described periodical changes in ovarian hormones throughout the menstrual cycle, which were simultaneously accompanied by alterations in symptom intensity. 30 In 2006 Cui et al. showed that peripheral blood estrogen levels in women and testosterone (TEST) levels in males suffering from IBS were lower than in healthy individuals. 29 In a study with rats, the colonic transit during the phases of the estrous cycle with increased estrogen and progesterone (PROG) levels was reduced. 31 Gonenne et al. found a significant acceleration of colonic transit by micronized PROG in postmenopausal women. 32 In older men and women, however, the prevalence of IBS seems to even out. 6 Hogan et al. showed that the motility of human colonic smooth muscle decreased in response to superfusion with estrogen. 33 These observations support the hypothesis that IBS might be associated with a sexual hormone disorder.
Given this background, the overall aim of the present study was to contribute to a better understanding of the effect of gonadal hormones on colonic contractile activity (CCA) and thus to a better understanding of the development of IBS and its sex distribution. In our in vitro model we aimed at (i) comparing the spontaneous colonic contractile activity (SCCA) of female and male naive Lewis rats, (ii) measuring the influence of the acute superfusion of the different gonadal hormones estradiol (EST), PROG and TEST on SCCA and (c) determining the acute effect of these gonadal hormones on the colonic contractile response to the neurotransmitters acetylcholine (ACh) and norepinephrine (NE).
MATERIALS AND METHODS

Animals and tissue collection
Female (n = 5) and male (n = 9) Lewis rats (Harlan, Horst, The Netherlands), weighting 160-220 g, were used for tissue collection. The procedures and animal care were performed according to the guidelines of the Department of Agriculture of the Canton of Berne, Switzerland. After a standard midline laparotomy the entire colon was resected. Anesthesia was applied with ketamine and xylazine s.c. (1 mL 100 g −1 bodyweight, mixture 1:1) (Ketasol and xylasol, Dr E. Graeub AG, Bern, Switzerland).
Tissue preparation
After removal, the colon was stored in a chilled modified Krebs-Ringer's bicarbonate solution (composition in mmol/L: sodium chloride 118.3; potassium chloride 4.7; calcium chloride 2.5; potassium phosphate 1.2; sodium bicarbonate 2.5; edetate calcium disodium 0.26; magnesium sulfate 2.5 and glucose 11.1) (Sigma Chemicals, Buchs, Switzerland), previously saturated with 95% oxygen and 5% carbon dioxide (Carbagas, Berne, Switzerland). The gut was fixed in a petri dish filled with a modified KrebsRinger's bicarbonate buffer solution, opened along the mesenteric border and pinned mucosa side up. The mesenteric tissue was cut out. Eight full thickness muscle strips of the distal colon were prepared in the orientation of the longitudinal muscle layer (0.4 cm × 1 cm).
Recording of contractile activity
The muscle strips were suspended vertically in 5 mL tissue chambers (Radnoti Glass Technology, Monrovia, CA, USA) filled with a modified Krebs-Ringer's bicarbonate solution, maintained at 37.5 C and bubbled with carboxygen. By means of silk loops, one end of each muscle strip was fixed to a glass hook at the bottom of the chamber whereas the other end was fixed above to a hook connected to a noncompliant force transducer (Radnoti) to measure the isometric force. During one experiment the activities of eight colon strips of one rat were recorded simultaneously. Contractile activity was monitored and stored digitally on a personal computer using special data acquisition system and software (AcqKnowledge; Biopac Systems, Goleta, CA, USA) (Fig. 1) .
Experimental design
After an approximately 60 min equilibration period with several washouts of the bath solution, each strip was incrementally stretched to its optimal length (Lo), defined as the length beyond which further stretching did not increase the amplitude of spontaneous activity. All experiments were then performed at this Lo. First, SCCA was measured for 5 min in each muscle strip. Then, rising doses of the pro-contractile agent ACh (20 nmol/L or 200 nmol/L or 2 μmol/L or 20 μmol/L) or the inhibitory agent NE (100 nmol/L or 1 μmol/L or 10 μmol/L) were administered to the organ chambers. Both neurotransmitters were added in a cumulative manner and every single concentration was incubated for 6 min. After this batch of experiments, all the chambers were washed out thoroughly both to avoid any interaction of the initial substances with subsequent drugs and any influence of the initially administered compounds on the following measurements of smooth muscle activity, and the muscle strips were allowed to recover their initial contractile activity. When spontaneous contractile activity became stable, chambers one and five were superfused with ethanol (ETH) 70% (10 μmol/L) (control), two and six with EST (10 μmol/L), three and seven with PROG (10 μmol/L), and four and eight with TEST (10 μmol/L) (all hormones diluted in 70% ETH). Hormones were incubated and equilibrated to Lo for 15 min. Thereafter, the same rising doses of ACh or of NE, as described above were added to the organ chambers and the resulting activities were recorded. Subsequently, all the chambers were flooded again with the saline solution three times to wash out any superfused substance before being equilibrated to Lo again. In a last set of experiments, the muscle strips were incubated for 15 min with the same sequence of hormones (or ETH as control) as mentioned before, but at a higher concentration (100 μmol/L), and ACh and NE were added in the same rising manner. At the end of the experiment, each muscle strip was measured (length), blotted dry and weighed to normalize recording for the tissue's wet weight. Length and weight are necessary to calculate the cross-sectional area (CSA) of the colon strips, which is a prerequisite for normalizing the SCCA. Thus, length and weight were excluded as potential confounders.
Drugs
The hormones EST, PROG and TEST as well as the neurotransmitters ACh and NE were purchased from Sigma Chemicals, Buchs, Switzerland.
Data analysis
SCCA was quantified as the integral of the generated force ( g × time as total area under the contractile curve) measured for a 5 min interval at Lo. The integral of force was calculated by computerized methodology using special software (AcqKnowledge, Biopac Systems, Goleta, CA, USA) and was normalized per mm 2 CSA for each muscle strip. The CSA was calculated using the following equation: 34, 35 
RESULTS
SCCA
A sex comparison showed that SCCA was significantly higher in females than in males (P < 0.001) (Fig. 2) .
Contractile response to neurotransmitters, sex comparison
Without any prior hormone superfusion, there is a progressive pro-contractile effect on SCCA with rising doses of ACh (20 nmol/L-20 μmol/L) and an inhibitory effect on SCCA with rising doses of NE (100 nmol/L-10 μmol/L) compared to the SCCA in both male and female rats. This effect is statistically significant for both sexes and both compounds (Tables 1,2 ). In contrast, no significant inter-sex difference of the stimulating effect of ACh (20 nmol/L-20 μmol/L) and the inhibitory effect of NE (100 nmol/ L-10 μmol/L) on SCCA could be observed.
Acute effect of gonadal hormones on spontaneous contractile activity, sex comparison
The comparison of the effects of EST, PROG and TEST versus ETH on SCCA between male and female Lewis rats did not reveal any statistically significant difference. Within the two groups, however, significant differences between the effect of the gonadal hormones and ETH were seen. Compared to ETH, the administration of EST led to a decrease in SCCA in female and male rats (P < 0.05). As for PROG, this gonadal hormone decreased the SCCA significantly only in female rats and at the high dose (100 μmol/ L) (P < 0.05). Furthermore, the administration of high-dose TEST resulted in a significant decrease of SCCA in male rats (P < 0.01) (Fig. 3) .
Acute effect of female gonadal hormones on contractile response to neurotransmitters, sex comparison
No consistent significant sex difference in contractile response to neurotransmitters (ACh 20 nmol/L-20 μmol/L or NE 100 nmol/L-10 μmol/L) could be observed after superfusion with any dose (10 and 100 μmol/L) of female gonadal hormones (EST or PROG). In female Lewis rats, the effect of the stimulating neurotransmitter ACh (20 nmol/L-20 μmol/L) on CCA declined when colon strips had been previously superfused with high-dose EST (100 μmol/L) (P < 0.01) (Fig. 4a) . In male Lewis rats such an effect after previous superfusion with EST could not be measured. EST (10 and 100 μmol/L) had no significant influence on the inhibition of CCA with NE (100 nmol/L-10 μmol/L). In comparison with previous ETH superfusion (10 and 100 μmol/L), neither sex showed any significant changes in CCA to raising doses of neurotransmitters (ACh 20 nmol/L-20 μmol/L or NE 100 nmol/L-10 μmol/L) after previous superfusion with PROG (10 and 100 μmol/L). 
Acute effect of TEST on spontaneous contractile activity and contractile response to neurotransmitters, sex comparison
There was no significant difference between male and female Lewis rats regarding the influence of TEST (10 and 100 μmol/L) on CCA when stimulated and inhibited respectively with neurotransmitters (ACh 20 nmol/L-20 μmol/L or NE 100 nmol/L-10 μmol/L). However, differences of the contractile response to neurotransmitters (ACh and NE) after TEST superfusion in comparison with ETH superfusion were observed within the sexes. In male rats, 10 and 100 μmol/L TEST intensified the effect of ACh partly in a significant manner (Fig. 4b) . In female rats, we could not observe any significant change of contractile response to ACh (20 nmol/L-20 μmol/L) after exposition with TEST (10 and 100 μmol/L) in comparison with ETH (10 and 100 μmol/L). No significant change of CCA in male Lewis rats was seen in response to NE (100 nmol/L-10 μmol/L) after previous superfusion with TEST (10 and 100 μmol/L). In contrast, when CCA of the female rats was inhibited by NE, its inhibitory effect was weakened after previous superfusion with highdose TEST compared to equivalent doses of ETH (P < 0.05) (Fig. 5 ).
DISCUSSION
Given a higher incidence of functional bowel disorders in the female population, a contributing effect of gonadal hormones on the development of IBS can be hypothesized. The aim of the present study was to characterize the influence of gonadal hormones on gastrointestinal motility in an in vitro model. Our results in an animal model with Lewis rats demonstrate that: (i) SCCA in females is significant higher than in males; (ii) acute EST superfusion has an inhibitory effect on SCCA in both sexes, whereas acute superfusion with PROG inhibits SCCA only in females. EST also has a negative effect on ACh stimulation, but only in females; and (iii) acute 68 AE 2.06**** *P < 0.01 vs SCCA (%), **P < 0.01 vs NE 100 nmol/L (%), ***P < 0.05 vs NE 1 μmol/L (%), ****P < 0.01 vs NE 1 μmol/L (%).
In vitro effect of NE in increasing concentrations (100 nmol/L or 1 μmol/L or 10 μmol/L) on CCA (in % of SCCA) of distal colonic longitudinal smooth muscle of female (n = 5) and male (n = 9) naive Lewis rats. TEST superfusion of male colonic muscle tissue inhibits SCCA. Interestingly, prior superfusion with the same hormone in males leads to a significantly higher reaction of CCA when stimulated with ACh. In females, TEST decreases the NE-induced inhibition on CCA.
SCCA
In the in vitro setting of our model, SCCA was considerably higher in naive female Lewis rats than in males. Our findings are consistent with the results of a former study performed by Heitkemper and Bond where ovariectomized rats with chronic estrogen replacement showed an increased gastric basal contraction frequency. 36 The underlying mechanisms for these differences in gastrointestinal contractility between the sexes could be explained by chronic exposure to different gonadal hormones, but could also be genetically determined via the inheritance of certain sex-specific alleles.
The acute influence of female gonadal hormones on SCCA and on the contractile response to the neurotransmitters ACh and NE
In order to characterize the specific influence of each single gonadal hormone on smooth muscle contractility in female and male rats, we determined the influence of acute superfusion of gonadal hormones on SCCA. In our experiments in Lewis rats, the acute superfusion of EST and PROG decreased SCCA in females in a dose-dependent manner. In male rats, only EST led to a significant reduction of SCCA. A similar effect of EST was observed for ACh-induced colonic smooth muscle contractility in females.
These findings imply that, in contrast to chronic exposure of female gonadal hormones to colon smooth muscle leading to hypercontractility, the acute superfusion of EST and PROG has an inhibitory effect on colonic smooth muscle contractility in rats. One explanation for this finding could be that there are different mechanisms triggered by the acute Figure 4 . In vitro effect of acetylcholine (ACh) on colonic contractile activity (CCA) (in % of spontaneous colonic contractile activity [SCCA]) of distal colonic longitudinal smooth muscle of (a) female naive Lewis rats after superfusion with 10 or 100 μmol/L estradiol (EST) or 10 or 100 μmol/L ethanol (ETH), respectively, **P < 0.01 (EST 100 μmol/L vs ETH 100 μmol/L) or (b) male rats after superfusion with 10 or 100 μmol/L testosterone (TEST) or 10 or 100 μmol/L ethanol (ETH), respectively, *P < 0.05 (TEST 10 μmol/L vs ETH 10 μmol/L and TEST 100 μmol/L vs ETH 100 μmol/L). SEM, standard error of the mean. and chronic application of hormones via nongenomic and genomic pathways.
EST has been shown to act on colonic smooth muscle via different pathways. The genomic effects involving the binding of EST to intracellular receptors with consecutive gene transcription and de novo protein synthesis have a latency of onset of 2-8 h. 37 Several authors have described non-genomic pathways of EST associated with rapid effects via various second messengers and modulating ion channels on different cell types. 33, 38, 39 Similarly, PROG also acts on intestinal smooth muscle cells via genomic and non-genomic pathways. 40, 41 The rapid action of PROG on colonic smooth muscle contractility, as seen in our in vitro experiments, can be explained with the non-genomic effects of PROG. This rapid mode of action which does not require gene transcription has already been described in several studies. 40, 42, 43 The exact molecular mechanism for the rapid inhibition of smooth muscle contractility by PROG is controversial. While some authors have found that PROG rapidly and reversibly decreased calcium entry through voltage-sensitive calcium currents, 40, 43 Xiao et al. described the nongenomic effect of PROG by a blockade of calcium release from intracellular stores without any effect on calcium influx. 44 These rapid non-genomic effects last for less than 60 min and are not seen in in vivo experiments where the cells are continuously exposed to PROG. This is due to a rapid desensitization of the cells as a result of prolonged exposure to PROG. 42 These findings could explain the discrepancies between the acute (as seen in in vitro studies) and chronic effects of PROG under physiological conditions. An explanation for the significant action of PROG on female colonic smooth muscle cells, but not on male cells, could be the different distribution or number of PROG receptors in the colon of females compared to males.
The inhibitory effect of the acute administration of female gonadal hormones on gastrointestinal smooth muscle contractility that contrasts with physiological chronic action has been investigated in several previous studies. In an in vitro study performed by Hogan et al. EST has been shown to decrease human colonic smooth muscle contractility, 33 while another study showed similar results in colonic circular muscle of rats. 45 These findings are consistent with the results obtained in our in vitro study with rats where EST inhibited the SCCA. However, EST has been demonstrated to inhibit smooth muscle contractility in other tissues, such as the gall bladder, 46 esophagus, 47 detrusor, 48, 49 aorta, 50 coronary arteries 51 and the carotid artery. 52 Bruce and Beshudi described enhanced gastrointestinal smooth muscle contractility following the chronic administration of EST in male rats. 53 An inhibitory effect of PROG has been reported for colonic, 31 ,54 gastric 55 and gall bladder smooth muscle. 56 PROG rapidly decreases the tension of intestinal smooth muscle strips in vitro 41 and high concentrations can completely inhibit the SCCA. 57 In consistency with our findings, this rapid inhibitory effect has been seen only with unphysiologically high concentrations of PROG that do not occur in vivo. 58 Bielefeldt et al. found that the IC50 for the inhibition of intestinal smooth muscle contractility is about ten to a hundredfold higher than the PROG serum concentrations found in pregnancy or the luteal phase of the menstrual cycle. 43 The in vitro studies that suggest an impaired smooth muscle contraction through the action of PROG 31, 40, 41 conflict with an in vivo study performed by Gonenne et al. which shows no significant change in colonic transit by the withdrawal of PROG or EST. 32 This again could be explained by the desensitization of the non-genomic pathways by prolonged hormonal exposure under physiological conditions. This latter finding supports earlier observations by Turnbull and Kamm who did not find any difference in gastrointestinal transit time during the estrous cycle. 59, 60 Thus, the influence of EST and PROG on human colonic transit time remains contradictory. The connection between contractility, motility and gastrointestinal transit time seems to underlie complex mechanisms and needs to be investigated further in future studies.
Decreased transit time could be due to decreased motility, increased proximal CCA or uncoordinated contractile patterns. Our findings, along with earlier studies, support the hypothesis that EST as well as PROG has a rapid inhibitory action on colonic smooth muscle contractility via non-genomic pathways, which differs from the chronic hormonal action seen under physiological conditions.
In our organ chamber experiments, EST lowered the pro-contractile action of ACh on CCA in females. This finding suggests that EST interferes with cholinergic (muscarinic) receptors. Muscarinic M2 and M3 receptors have been identified in rat colonic smooth muscle. 61 EST could influence the adenylyl cyclase activity triggered by the M2 receptor or interfere with mechanisms mediated by M3 such as the augmentation of phosphoinositide hydrolysis. 62 In contrast, we could not show a significant influence of EST and PROG on NE-induced inhibition of colonic smooth muscle contractility. So far, there have not been any studies investigating the effect of EST or PROG on NE-receptors in colonic smooth muscle. EST leads to a suppression of beta-adrenoceptor-mediated relaxation in the vascular smooth muscle without modifying the beta-adrenoceptor binding characteristics. 63 In the myometrium, estrogen increases alphaadrenergic sensitivity, also without changes in the alpha-receptors. 64 This leads to the assumption that the possible modulation of estrogen on NE-induced changes in smooth muscle contractility is due to changes in the postreceptor response. Thus, EST does not seem to have a direct influence on NE receptors. Postreceptor pathways in colonic smooth muscle may differ from those in the aorta or the uterus.
Influence of TEST on SCCA and on contractile response to the neurotransmitters ACh and NE
The superfusion of TEST resulted in a significant decrease of SCCA only in male Lewis rats, but not in females. Our results contrast with a recent study performed by Gonzáles-Montelongo et al. where physiological concentrations (10 nmol/L) of TEST had a stimulating effect on spontaneous contractility in longitudinal colonic smooth muscle of male Swiss CD1 mice. 65 In this study, TEST acted on colonic longitudinal smooth muscle via non-genomic induction of calcium sensitization. The reason for the contradictory results could be a dose-dependent action of TEST. In our study, we used supraphysiological concentrations.
Similar to EST, TEST also acts via genomic (requiring gene transcription) and quick non-genomic pathways. 66, 67 Our results showed a pro-contractile effect of TEST on ACh-induced contractions in male rats. This effect was also observed in the previously mentioned study by Gonzáles-Montelongo, where incubation of colonic smooth muscle strips with TEST augmented the contractile response to carbachol 1 μmol which, like ACh, acts as a muscarinic agonist. 65 Furthermore, we observed a decreasing effect of TEST on NE-induced relaxation in female animals.
One of the limitations of our study is the fact that we used supraphysiological concentrations of gonadal hormones. We deliberately chose these doses in order to detect even minor effects of the gonadal hormones on GI motility in our in vitro model. In former in vitro studies investigating the effect of gonadal hormones on smooth muscle contractility, hormonal doses in the same range were used. 33, 40, 43 To confirm our findings in a more physiological set-up, further studies have to be conducted. The number of animals (female n = 5, male n = 9) used in our study is small, which could lead to a lower informative value. However, thanks to the high statistical significance of our results, the low numbers in our study should not have any major negative influence on the end results.
In conclusion, our study showed that: (i) SCCA is significantly higher in female naive animals than in males; (ii) the acute superfusion of colonic muscle strips with EST is associated with a decrease in SCCA in both sexes, whereas PROG leads to a decrease in SCCA only in females. The ACh-triggered increase of CCA is lowered by EST only in females; and (iii) TEST leads to a decrease in SCCA only in males, but also augments the ACh-induced CCA in males, whereas the NE-induced inhibition of SCCA is decreased by the administration of TEST in females.
These findings support our hypothesis of a strong influence of gonadal hormones on CCA and may contribute to the better understanding of the observation that women seem to be more prone to developing functional bowel disorders. The results of our study also suggest that gonadal hormones have an acute local effect on CCA, which could be a step towards a possible future new therapeutic approach in IBS. In this context, further studies are needed to characterize the precise cellular and molecular mechanisms and pathways underlying our present observations. Our in vitro organ chamber model may serve as a useful tool to further investigate this topic.
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